肝细胞癌组织细胞因子信号转导抑制因子-1表达的研究

doi:10.3969/j.issn.1672-5069.2010.06.008

实用肝脏病杂志 ›› 2010, Vol. 13 ›› Issue (6): 420-423.doi: 10.3969/j.issn.1672-5069.2010.06.008

肝细胞癌组织细胞因子信号转导抑制因子-1表达的研究

张荣贵,张广田,徐丽

100038 北京市羊坊店医院内科

收稿日期:2010-08-02 修回日期:2016-04-18 出版日期:2010-12-10 发布日期:2016-04-18
作者简介:张荣贵男，37岁，医学硕士，主治医师。主要从事消化道肿瘤的研究。E-mail：zhangrg678@sina.com

Expressions of suppressor of cytokine signaling 1 in hepatocellular carcinoma tissues

ZHANG Ronggui，ZHANG Guangtian，XU Li

Yangfangdian Hospital，Beijing 100038，China

Received:2010-08-02 Revised:2016-04-18 Online:2010-12-10 Published:2016-04-18

摘要/Abstract

摘要： 目的探讨细胞因子信号转导抑制因子（SOCS1）、血管内皮生长因子受体（VEGFR）-2和表皮生长因子受体（EGFR）在肝硬化、肝细胞癌组织中的表达变化。方法采用免疫组化法检测63例HCC组织、51例癌周肝组织、11例肝硬化组织及11例正常肝组织SOCS1蛋白的表达；另分别检测VEGFR2和EGFR在27例和41例HCC组织中的表达情况。结果癌周肝组织中SOCS1蛋白表达为阴性1例，弱阳性15例，阳性30例，强阳性5例，HCC组织中SOCS1蛋白表达为阴性11例，弱阳性38例，阳性14例，癌周肝组织中SOCS1蛋白表达强度显著高于HCC组织（P<0.01）；SOCS1蛋白在肝硬化组织和正常肝组织中无表达；SOCS1表达在瘤体大小间（瘤体<5cm和≥5cm）有显著性差异（P<0.001）；SOCS1蛋白在HCC组织中的表达与VEGFR2和EGFR的表达无显著相关性（P>0.05）。结论 SOCS1蛋白表达与HCC的发生发展密切相关。

关键词: 肝细胞癌, 细胞因子信号转导抑制因子1, 血管内皮生长因子受体, 表皮生长因子受体

Abstract: Objective To investigate the expressions of suppressor of cytokine signaling 1（SOCS1），vascular endothelial growth factor receptor（VEGFR2）and epidermal growth factor receptor（EGFR）in liver cirrhosis and hepatocellular carcinoma tissues. Methods The expression of SOCS1 were examined with immunohistochemical technique in the specimens from 63 HCC tissues，51 paracarcinoma tissues，11 LC tissues，and 11 normal liver tissues，and the expressions of VEGFR2 and EGFR in 27 and in 41 HCC tissues，respectively. Results The positive rate of SOCS1 expression was significantly higher in paracarcinoma tissues than that in the HCC tissues（P<0.001），and it was not positive in LC and normal liver tissues；The expression of SOCS1 was significantly correlated with the size of tumor（P<0.001）；There was no significant correlation between the expression of SOCS1 and the expression of VEGFR2 or EGFR in HCC tissues. Conclusions The expression of SOCS1 is closely correlated with the occurrence and development of HCC.

Key words: Hepatocellular carcinoma, Suppressor of cytokine signaling 1, Vascular endothelial growth factor receptor, Epidermal growth factor receptor

张荣贵,张广田,徐丽. 肝细胞癌组织细胞因子信号转导抑制因子-1表达的研究[J]. 实用肝脏病杂志, 2010, 13(6): 420-423.

ZHANG Ronggui，ZHANG Guangtian，XU Li. Expressions of suppressor of cytokine signaling 1 in hepatocellular carcinoma tissues[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2010, 13(6): 420-423.

参考文献

[1] YANDAVA CN，PILLARI A，DRAZEN JM. Radiation hybrid and cytogenetic mapping of SOCS1 and SOCS2 to chromosomes 16p13 and 12q，respectively[J]. Genomics，1999，61:108-111.
[2] TROP S，DE SEPULVEDA P，ZUNIGA-PFLUCKER JC， et al. Overexpression of suppressor of cytokine signaling-1 impairs pre-T-cell receptor-induced proliferation but not differentiation of immature thymocytes[J]. Blood，2001，97:2269-2277.
[3] YOSHIDA T，OGATA H，KAMIO M，et al. SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis[J]. J Exp Med，2004，199（12）:1701-1707.
[4] OKOCHI O，HIBI K，SAKAI M，et al. Methylation-mediated silencing of SOCS-1 gene in hepatocellular carcinoma derived from cirrhosis[J]. Clin Cancer Res，2003，9（14）: 5295-5298.
[5] TANNAPFEL A，ANHALT K，HAUSERMANN P，et al. Identification of novel proteins associated with hepatocellular carcinomas using protein microarrays[J]. J Pathol，2003，201:238-249.
[6] NAGAI H，KIM YS，KONISHI N，et al. Combined hypermethylation and chromosome loss associated with inactivation of SSI-1/SOCS-1/JAB gene in human hepatocellular carcinomas[J]. Cancer Lett，2002，186:59-65.
[7] YOSHIKAWA H，MATSUBARA K，QIAN GS，et al. SOCS-1，a negative regulator of the JAK/STAT pathway，is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity[J]. Nat Genet，2001，28:29-35.
[8] KO E，KIM SJ，JOH JW，et al. CpG island hypermethylation of SOCS-1 gene is inversely associated with HBV infection in hepatocellular carcinoma[J]. Cancer Lett，2008，271（2）:240-250.
[9] BOCK CT，TOAN NL，KOEBERLEIN B，et al. Subcellular mislocalization of mutant hepatitis B X proteins contributes to modulation of STAT/SOCS signaling in hepatocellular carcinoma[J]. Intervirology，2008，51（6）:432-443.
[10] HICKLIN DJ，ELLIS LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis[J]. J Clin Oncol，2005，23:1011-1027.
[11] AKAGI M，KAWAGUCHI M，LIU W，et al. Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells[J]. Br J Cancer，2003，88（5）:796-802.

[1]	曹策, 郁义星, 王贝贝, 赵卫峰. 增强磁共振成像联合血清甲胎蛋白和脱-γ-羧基凝血酶原诊断肝细胞癌临床价值探讨[J]. 实用肝脏病杂志, 2019, 22(6): 896-899.
[2]	朱俊, 丁莹, 王世清, 张野, 刘野, 刘泽刚. 围手术期应用乌司他丁治疗对肝细胞癌患者肝切除术后外周血Th22细胞百分比和血浆白细胞介素-22的影响*[J]. 实用肝脏病杂志, 2019, 22(5): 720-723.
[3]	王刚, 赵洪波, 朱亚玲, 蒋保三, 张越美, 刁勇. 基于数据库分析肝细胞癌细胞XPO5基因水平变化及其临床意义*[J]. 实用肝脏病杂志, 2019, 22(5): 724-727.
[4]	戴青云, 王润东, 荚卫东. 术前预后营养指数评估肝细胞癌患者肝切除术后早期肿瘤复发价值探讨^*[J]. 实用肝脏病杂志, 2019, 22(4): 561-564.
[5]	杨富存, 尚怀学, 盖永浩. 钆塞酸二钠增强磁共振扫描诊断肝脏局灶性病变研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 577-580.
[6]	彭新健, 肖玉辉, 许斯鼎, 石荣跃, 王耀政, 王瑜琳. 放射性肝损伤患者肝脏磁共振扩散加权成像表现特征分析[J]. 实用肝脏病杂志, 2019, 22(3): 373-376.
[7]	乔志忠. 超声造影定量分析鉴别肝脏局灶性结节性增生与原发性肝癌初步探讨[J]. 实用肝脏病杂志, 2019, 22(3): 421-424.
[8]	朱光曦（综述）, 文良志, 陈东风（审校）. 非酒精性脂肪性肝病相关肝细胞癌发病机制研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 453-456.
[9]	王虎明,樊东升,徐杰,刘险峰,周宁,丽敏,包娜娜. 肝细胞癌患者癌组织miRNA-30c水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(2): 248-251.
[10]	幸奠奎,程婧. ¹⁸F-FDG PET/CT检查指标预测肝细胞癌微血管侵犯临床价值研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 252-254.
[11]	王秀清,马艳君,詹晋莉. 肝动脉化疗栓塞术联合超声引导下微波消融术治疗特殊部位原发性肝癌患者疗效及安全性分析 ^*[J]. 实用肝脏病杂志, 2019, 22(2): 260-263.
[12]	张小舟,帅领,王庆大,杨楠. 接受TACE治疗的肝细胞癌患者血清miR-335水平变化及其对预后判断的价值分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 268-271.
[13]	王朝霞,关珂,付三仙,王慧杰. 肠内肠外联合营养支持治疗肝细胞癌患者围术期临床研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 272-275.
[14]	赵西太综述,聂青和审校. 循环microRNA早期诊断肝细胞癌研究现状及方法学探讨[J]. 实用肝脏病杂志, 2019, 22(2): 297-300.
[15]	范建高. 2018年《实用肝脏病杂志》精彩回顾[J]. 实用肝脏病杂志, 2019, 22(1): 1-3.

肝细胞癌组织细胞因子信号转导抑制因子-1表达的研究

Expressions of suppressor of cytokine signaling 1 in hepatocellular carcinoma tissues

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价